Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing and Issue of Equity

9 Nov 2017 18:19

RNS Number : 1101W
Diurnal Group PLC
09 November 2017
 

9 November 2017

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealing and Issue of Equity

 

On 8 November 2017, Diurnal issued a total of 109,296 new ordinary shares of 5 pence in the Company ("Shares") under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), including 69,565 new Shares to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of Shares issued

Nature of issuance

Martin Whitaker

69,565

Vesting of Deferred Bonus Award

 

The Shares issued were awarded on a deferred basis on 8 November 2016, as previously notified on 9 November 2016. Upon receipt of these shares, Martin Whitaker subsequently sold 33,650 ordinary shares to settle payment of all tax and NI requirements in relation to the award as set out in the notification below.

 

Issue of equity

 

Application has been made to AIM for the admission of the 109,296 new Shares, which is anticipated to occur at 8.00am on 15 November 2017. The Company has also made application for admission to AIM at the same time of the following shares that have previously been duly issued and allotted but not admitted to trading: 110,000 new Shares issued on 12 April 2017 in respect of the exercise of options by a former employee at an exercise price of 43.77p per new Share; 10,791 new Shares issued on 7 September 2017 in respect of the vesting of shares to Mr John Goddard, NED of the Company, at a price of 5p per new Share (as announced on 7 September 2017); 100,000 new Shares issued on 21 September 2017 in respect of the exercise of options by a former director at an exercise price of 0.2p per new Share; and 29,000 new Shares issued on 21 September 2017 in respect of the exercise of options by an employee at an exercise price of 43.77p per new Share.

 

Following admission of the new Shares, the Company's total issued share capital will be 52,569,846 Ordinary Shares. Therefore, the total number of voting rights in the Company is 52,569,846. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

 

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Vesting of awards under the Diurnal Group plc Long Term Incentive Plan as follows:

 

EMI deferred bonus award over 9,730 ordinary shares.

 

Non-EMI deferred bonus award over 59,835 ordinary shares.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

120p

9,730

120p

59,835

d)

 

Aggregated information

- Aggregated volume

69,565 ordinary shares

- Price

£83,478.00

e)

 

Date of the transaction

 

8 November 2017

f)

 

Place of the transaction

 

Off market

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

 

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Sale of 33,650 shares

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

134.7p per share

33,650

d)

 

Aggregated information

- Aggregated volume

33,650 ordinary shares

- Price

£45,326.55

e)

 

Date of the transaction

 

8 November 2017

f)

 

Place of the transaction

 

XLON

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield

Corporate Broking: James Black

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley / Duncan Monteith

Corporate Broking: Tom Salvesen

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSIFAUFWSEFF
Date   Source Headline
30th Apr 20193:40 pmRNSHolding(s) in Company
30th Apr 20192:43 pmRNSHolding(s) in Company
26th Apr 20195:52 pmRNSDirector Dealings and Issue of Equity
26th Apr 20193:10 pmRNSHolding(s) in Company
25th Apr 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway
24th Apr 20197:00 amRNSGrant of Orphan Drug Designation in Australia
11th Apr 20197:00 amRNSPositive Scientific Advice from EMA for Chronocort
28th Mar 20197:00 amRNSDiurnal signs marketing and distribution agreement
28th Mar 20197:00 amRNSInterim Results
20th Mar 20197:00 amRNSUpdate on Alkindi US development
25th Feb 20197:00 amRNSSubmission of MAA for Alkindi and Second Patent
11th Feb 201911:00 amRNSNotice of Interim Results
17th Jan 20197:00 amRNSDirector Dealings
16th Jan 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice
10th Jan 201912:18 pmRNSStatement regarding Price Movement
10th Jan 20197:00 amRNSGrant of second US patent for Chronocort
24th Dec 20187:00 amRNSDirector Dealings and Issue of Equity
12th Dec 20184:02 pmRNSDirector Dealings
11th Dec 20187:00 amRNSRegulatory package for Scientific Advice in Europe
4th Dec 20181:08 pmRNSDirector/PDMR Shareholding
14th Nov 201811:38 amRNSResults of Annual General Meeting
14th Nov 201810:16 amRNSIssue of Equity and Exercise of Options
18th Oct 20187:15 amEQSHardman & Co Research: Diurnal Group (DNL): Unexpected Phase III trial outcome
17th Oct 20187:00 amRNSUpdate on late-stage development pipeline
8th Oct 20184:00 pmRNSPosting of Annual Report and AGM Notice
8th Oct 20182:45 pmRNSSMC Approves The Use of Alkindi
8th Oct 20187:00 amRNSHeadline Data for Chronocort European Phase III
5th Oct 20187:00 amRNSFirst patients enrolled in US Chronocort Phase III
20th Sep 20187:00 amRNSResults for the year ended 30 June 2018
15th Aug 201811:11 amRNSUpdate on Alkindi® in Germany
10th Jul 20181:36 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSNotice of Results
18th Jun 20184:54 pmRNSDirector/PDMR Shareholding
18th May 20183:33 pmRNSDirector Dealings
18th May 20181:11 pmRNSAppointment of NOMAD and Joint Broker
15th May 20188:13 amRNSLaunch of Alkindi for paediatric AI in Germany
11th May 20182:41 pmRNSDirector Declaration
17th Apr 20183:58 pmRNSHolding(s) in Company
5th Apr 20182:08 pmRNSDirector/PDMR Shareholding
5th Apr 20188:01 amRNSDirector/PDMR Shareholding
3rd Apr 20182:39 pmRNSResult of GM and Completion of £10.5m Placing
21st Mar 20187:15 amRNSHardman & Co: New capital funds commercial plans
20th Mar 20185:20 pmRNSPlacing Update
14th Mar 20188:47 amRNSProposed Placing
12th Mar 20187:00 amRNSAppointment of CRO to support US Chronocort trials
12th Mar 20187:00 amRNSHalf-year Report
22nd Feb 20187:00 amRNSDiurnal announces grant of first patents in Japan
19th Feb 20187:00 amRNSCommercialisation agreement in Australia and NZ
13th Feb 20187:00 amRNSEuropean marketing authorisation for Alkindi®
12th Feb 20187:00 amRNSCompletion of patient enrolment in EU Phase III

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.